Rituximab responsive immune thrombocytopenic purpura in an adult with underlying autoimmune lymphoproliferative syndrome due to a splice-site mutation (IVS7+2 T>C) affecting the Fas gene

European Journal of Haematology

Volumn 79, Issue 4, 2007, Pages 363-366

  Wei, Andrew ^a   Cowie, Tiffany ^b  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Autoimmune lymphoproliferative syndrome; Fas; Immune thrombocytopenic purpura; Rituximab; TNFRSF6

Indexed keywords

AZATHIOPRINE; DEATH RECEPTOR; FAS ANTIGEN; IMMUNOGLOBULIN; PREDNISOLONE; RITUXIMAB;

ADULT; ANAMNESIS; ARTICLE; AUTOIMMUNE DISEASE; CASE REPORT; GENE MUTATION; HEMOLYTIC ANEMIA; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; LABORATORY TEST; LYMPHADENOPATHY; LYMPHOPROLIFERATIVE DISEASE; MALE; PRIORITY JOURNAL; RNA SPLICING; TREATMENT RESPONSE;

ADULT; ANTIBODIES, MONOCLONAL; ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; GENETIC DISEASES, INBORN; HUMANS; IMMUNOSUPPRESSION; LYMPHOCYTE COUNT; LYMPHOPROLIFERATIVE DISORDERS; MALE; POINT MUTATION; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RNA SPLICE SITES; SPLENECTOMY;

EID: 34548590302     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2007.00924.x     Document Type: Article

References (13)

1. Portielje JE, Westendorp RGJ, Kluin-Nelemans HC, Brand A. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 2001 97: 2549 54.
2. Kasahara Y, Wada T, Niida Y, et al. Novel Fas (CD95/APO-1) mutations in infants with a lymphoproliferative disorder. Int Immunol 1998 10: 195 202.
3. Fisher GH, Rosenberg FJ, Straus SE, Dale JK, Middleton LA, Lin AY, Strober W, Lenardo MJ, Puck JM. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 1995 81: 935 46.
4. http://research.nhgri.nih.gov/ALPS/?CFID=15112694&CFTOKEN=18107643
5. Wang J, Zheng L, Lobito A, Chan FK, Dale J, Sneller M, Yao X, Puck JM, Straus SE, Lenardo MJ. Inherited human caspase 10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II. Cell 1999 98: 47 58.
6. Straus SE, Jaffe ES, Puck JM, et al. The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. Blood 2001 98: 194 200.
7. Rao VK, Carrasquillo JA, Dale JK, Bacharach SL, Whatley M, Dugan F. Fluorodeoxyglucose positron emission tomography (FDG-PET) for monitoring lymphadenopathy in the autoimmune lymphoproliferative syndrome (ALPS). Am J Hematol 2006 8: 81 5.
8. Kojouri K, Vesely SK, Terrell DR, George JN. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood 2004 104: 2623 34.
9. Heelan BT, Tormey V, Amlot P, Payne E, Mehta A, Webster AD. Effect of anti-CD20 (rituximab) on resistant thrombocytopenia in autoimmune lymphoproliferative syndrome. Br J Haematol 2002 118: 1078 81.
10. Rao VK, Dugan F, Dale JK, Davis J, Tretler J, Hurley JK, Fleisher T, Puck J, Straus SE. Use of mycophenolate mofetil for chronic, refractory immune cytopenias in children with autoimmune lymphoproliferative syndrome. Br J Haematol 2005 129: 534 8.
11. Cooper N, Stasi R, Cunningham-Rundles S, Feuerstein MA, Leonard JP, Amadori S, Bussel JB. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol 2004 125: 232 9.
12. Muschen M, Re D, Jungnickel B, Diehl V, Rajewsky K, Kuppers R. Somatic mutation of the CD95 gene in human B cells as a side-effect of the germinal center reaction. J Exp Med 2000 18: 192.
13. Hainsworth JD, Burris HA, 3rd., Morrissey LH, Litchy S, Scullin DC Jr., Bearden JD, 3rd., Richards P, Greco FA. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood 2000 15: 95.